Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVES: Major advances have recently been made in the treatments of cancer, which now also have the potential to improve patients' health-related quality of life (HRQOL). We propose the time to HRQOL improvement (TTI) and the time to sustained HRQOL improvement (TTSI) as potentially important cancer outcomes to be used in longitudinal HRQOL analyses. STUDY DESIGN AND SETTING: As proof of principle, we defined TTI and TTSI, using the Fine-Gray model to include competing risks in estimates, in a case study in real life of a cohort of newly diagnosed patients with cancer receiving a targeted therapy. HRQOL was evaluated before and during therapy with six assessments over a 24-month period, using the well-validated European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30. RESULTS: For each assessed HRQOL domain, we assessed TTI and TTSI and estimated the cumulative incidence of patients' clinically meaningful improvements, also accounting for the occurrence of competing events. CONCLUSION: TTI and TTSI are potentially important outcomes in the era of modern anticancer therapies. The analysis of TTI and TTSI by competing risks approach will further add to the statistical methods that can be used to inform on the impact of cancer therapies on patients' HRQOL.

Original publication

DOI

10.1016/j.jclinepi.2020.06.016

Type

Journal article

Journal

J clin epidemiol

Publication Date

11/2020

Volume

127

Pages

9 - 18

Keywords

Cancer, Competing risks, Health-related quality of life, Immunotherapy, Targeted therapies, Time to HRQOL improvement, Time to sustained HRQOL improvement, Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Kaplan-Meier Estimate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Middle Aged, Neoplasms, Progression-Free Survival, Proof of Concept Study, Proportional Hazards Models, Pyrimidines, Quality Improvement, Quality of Life, Time Factors, Treatment Outcome, Young Adult